Putative preneoplastic foci in the XXXX prostate.

@entity1 @entity263 @entity96 @entity5 @entity368 @entity189 @entity1759 @entity1613 @entity4623
Our knowledge of @entity263 is less well-defined than our knowledge of @entity5 of other organs. In the colon, for example, morphological criteria to identify @entity189 in situ and some putative @entity1613 are clear; phenotypic differences in the expression of enzymes and antigens are documented in experimental models and are starting to be defined in @entity1 . Experimental models of @entity96 and colon show evidence that "enzyme-altered foci" are preneoplastic. In these organs, the "normal" context is much clearer than in the prostate. In contrast, in the prostates of @entity1 in the same age range as those who develop @entity263 , morphological aberrations are almost always present, diverse, and poorly understood. Murphy and Gaeta said that, "in the study of @entity4623 ..., almost every aspect remains controversial...[and].... many of the 'known facts' concerning @entity4623 are poorly documented..." While being aware that the definitions of all benign and malignant lesions of the prostate are based on complex morphological criteria which must form the contemporary context for comparisons, our laboratory is searching for markers that will permit the identification of putative @entity1613 in the prostate. In our opinion, these changes will not be found most efficiently, if they are present at all, in long established cell lines, advanced @entity189 , or serially transplantable xenografts of primary @entity263 . Our preliminary data suggest that several enzyme histochemical and immunohistochemical approaches are worthy of study. Markers that show promise include acid phosphatase, 5'-nucleotidase, @entity368 aminopeptidase, and @entity1759 .(ABSTRACT TRUNCATED AT 250 WORDS)
